Regencell Bioscience Holdings annual ebitda
2020
2021
2022
2023
2024
2025
Regencell Bioscience Holdings EBITDA Growth & History (RGC)
Regencell Bioscience Holdings's calculated EBITDA was −$3.4M for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | −$3.4M | $613,896 | — |
| 2024 | 2024-06-30 | −$4.0M | $1.5M | — |
| 2023 | 2023-06-30 | −$5.5M | $1.5M | — |
| 2022 | 2022-06-30 | −$7.0M | −$5.7M | — |
| 2021 | 2021-06-30 | −$1.4M | −$552,051 | — |
| 2020 | 2020-06-30 | −$802,855 | — | — |
Regencell Bioscience Holdings quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Regencell Bioscience Holdings ebitda trends
Over the last five reported fiscal years, Regencell Bioscience Holdings's ebitda decreased from −$802,855 to −$3.4M, a change of −$2.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings filings at SEC.gov ↗